

Controlling the pandemic during the SARS-CoV-2 vaccination rollout: a modeling study

João Viana, MSc^{1,2}, Christiaan H. van Dorp, PhD³, Ana Nunes, PhD^{2,4}, Manuel C. Gomes, PhD², Michiel van Boven, PhD¹, Mirjam E. Kretzschmar, PhD¹, Marc Veldhoen, PhD⁵, and Ganna Rozhnova, PhD^{*1,4}

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

²Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal

³Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los Alamos, New Mexico, USA

⁴BioISI—Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal

⁵Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

March 24, 2021

*Corresponding author:

Dr. Ganna Rozhnova
Julius Center for Health Sciences and Primary Care
University Medical Center Utrecht
P.O. Box 85500 Utrecht
The Netherlands
Email: g.rozhnova@umcutrecht.nl
Phone: +31 631117965

Abstract

There is a consensus that mass vaccination against SARS-CoV-2 will ultimately end the COVID-19 pandemic. However, it is not clear when and which control measures can be relaxed during the rollout of vaccination programmes. We investigate relaxation scenarios using an age-structured transmission model that has been fitted to age-specific seroprevalence data, hospital admissions, and projected vaccination coverage for Portugal. Our analyses suggest that the pressing need to restart socioeconomic activities could lead to new pandemic waves, and that substantial control efforts prove necessary throughout 2021. Using knowledge on control measures introduced in 2020, we anticipate that relaxing measures completely or to the extent as in autumn 2020 could launch a wave starting in April 2021. Additional waves could be prevented altogether if measures are relaxed as in summer 2020 or in a step-wise manner throughout 2021. We discuss at which point control of COVID-19 would be achieved for each scenario.

Introduction

Mass vaccination against SARS-CoV-2 that started in Europe in December 2020/January 2021 [1] brings hope that the COVID-19 pandemic will end in 2021. Although the progress towards this goal is on the right track [2], many governments in Europe continue limiting socioeconomic activities to control the pandemic. Despite elaborate national vaccination schedules, it remains unclear when and which control measures can be relaxed and at which point the control of the pandemic will be achieved as the vaccination is rolled out in 2021. The understanding of how relaxation policies might affect the transmission of SARS-CoV-2 is further hampered by the emergence of novel variants [3, 4] that have a selective advantage, such as increased transmissibility [5–7] or the ability to reduce rapid neutralisation by the host [8]. For example, the current restrictions in Europe [9] are in part caused by a more transmissible [5–7] and potentially more pathogenic [10, 11] B.1.1.7 variant that originated in the UK and is quickly gaining dominance in other countries including Portugal [12, 13].

The vaccines that have been approved in Europe [14] show consistently high efficacy against severe disease, hospitalization and death in trials [15–17] and equally high effectiveness in real-world settings [18–22]. Multiple studies are under way to establish infection-blocking properties of these vaccines. Preliminary analyses of the national vaccination programme in Israel indicate that the effectiveness of the Pfizer-BioNTech vaccine against asymptomatic SARS-CoV-2 infections could be as high as 94% [21], as announced recently by the Israel Ministry of Health, Pfizer Inc and BioNTech SE. The recent Danish cohort study on long-term care facility residents and healthcare workers suggests that the effectiveness of the Pfizer-BioNTech vaccine based on a positive PCR test for SARS-CoV-2 is 64% and 90% beyond seven days of second dose in the two groups, respectively [19]. Similar results were found in a study among healthcare workers in England where the effectiveness of the Pfizer-BioNTech vaccine against symptomatic and asymptomatic infection was 86% seven days after two doses [22]. Based on the data from Israel, the effectiveness of the same vaccine against infection with SARS-CoV-2 was shown to be 51% 13-24 days after one

34 dose [20]. Finally, in an analytical study by Lipsitch et al [23], the lower bound for the efficacy against transmission
35 for one dose of Moderna vaccine was estimated at 61% but it could possibly be considerably higher, especially after
36 two doses.

37 The consequences of relaxing control measures such as e.g., physical distancing, school closure, mask-wearing, test-
38 and-trace and isolation, will depend on several factors, including the properties of vaccines deployed in a given
39 country, specific vaccination schedules and speeds of vaccine rollout, but also the past epidemiology of SARS-CoV-
40 2 that defines a proportion of the population protected after natural SARS-CoV-2 infection [24, 25]. All these
41 factors are naturally country-dependent and will play a major role in how the pandemic will develop under different
42 relaxation scenarios [26–29] and how quickly the control of COVID-19 will be gained in specific countries throughout
43 2021 and possibly beyond. To make a few distinctive examples, we recall Israel which has the highest vaccination
44 rate worldwide so that, on average, every person has received at least one vaccine dose by mid-March 2021 [1]
45 and Manaus in Brazil, where the levels of protection by natural infection close to the theoretical herd immunity
46 threshold were achieved prior to the start of mass vaccination [30].

47 An extensive body of literature addresses the challenges of modelling real-time fast-moving COVID-19 pandemic [31].
48 Mathematical transmission models robustly calibrated to available data are among the best tools available to provide
49 input into the discussion on the response to the COVID-19 pandemic [32–43] and they will continue to play an
50 important role in making decisions surrounding the relaxation of measures in 2021 [26–29]. Several modeling
51 studies provided support for the development of COVID-19 vaccines and early planning of vaccination scenarios
52 and rollouts [44–48], but these models typically assumed that a large proportion of the population is vaccinated
53 instantaneously and/or did not focus on relaxation strategies. More recently, organized teams of modeling experts
54 supporting decision-makers over health emergencies in China and the UK evaluated the roadmap scenarios for
55 relaxation of control measures in these countries in light of ongoing mass vaccination [26–28].

56 The present study makes a contribution towards better understanding of when and which control measures can be
57 relaxed as mass vaccination programmes progress in 2021. We take Portugal as a case study where good quality data
58 for model parameterization are available but, apart from efforts of genomic surveillance [49], there are no dedicated
59 COVID-19 modeling studies for informing policymaking in this country [50]. Using an age-structured transmission
60 model that has been fitted in a Bayesian framework to the data from various sources (age-specific hospitalizations
61 and seroprevalence, social contact and demographic data, national vaccination plan and vaccine rollout data etc.),
62 we investigate future pandemic trajectories under several alternative relaxation scenarios throughout 2021. Among
63 the explored relaxation strategies are lifting measures to the same extent as in summer 2020 and later on in autumn
64 2020, the complete lifting of measures and combinations of these. We evaluate the impact of each scenario on
65 the epidemic dynamics as quantified by projected hospital admissions, the time-dependent effective reproduction
66 number, population immunization level due to natural infection and vaccination, and timing of reaching control
67 of COVID-19 in Portugal. Finally, we discuss the implications of our findings for the post-pandemic dynamics of

68 SARS-CoV-2.




Figure 1. Model fit to COVID-19 hospitalizations. The age-stratified daily hospital admission data are shown as red dots. The median trajectories estimated from the model are shown as the black lines. The gray shaded regions correspond to 95% Bayesian prediction intervals based on 2,000 parameter samples from the posterior distribution. Hospital admissions were estimated for 10 age groups (see Methods). For presentation purposes, here we grouped hospitalizations for ages [0,5), [5,10), [10,20).

69 Results

70 Model calibration

71 The model was fitted to age-stratified COVID-19 hospitalization data in the period from 26 February 2020 till 15
72 January 2021 and cross-sectional age-stratified SARS-CoV-2 seroprevalence data assessed from 21 May 2020 till 8
73 July 2020. The model reproduces well the age-specific hospital admissions (Figure 1) featuring (i) the first pandemic
74 wave (March-April 2020), (ii) relatively low epidemic activity (May-August 2020), (iii) the second pandemic wave
75 (September-mid-December 2020), (iv) the third wave that started in mid-December 2020 and was still ongoing on
76 15 January 2021 [51]. The estimated hospitalization rates increase with age from 0.12 (95%CrI 0.07-0.23) per year
77 for children under 5 years of age to 14.24 (95%CrI 9.91–21.23) per year for persons above 80 years (Figure S1). In
78 agreement with other studies [52, 53], the estimated susceptibility to SARS-CoV-2 increases with age (Figure S2).
79 The meaning of model parameters is given in Tables S2 and S4, and their estimates are shown in Figures S1 and
80 S2.

81 The model also reproduces well the age-specific and total seroprevalence in the population (Figure 2). The estimated
82 age-specific seroprevalence ranged between 1.77% (95%CrI 0.98–2.91%) for 1 to 10 years old children to 4.61%

83 (95%CrI 3.47–5.91%) for 20 to 40 years old adults (Figure 2 a). The total seroprevalence steadily increased with
84 time reaching 19.37% (95%CrI 14.82–24.57%) on 15 January 2021 (Figure 2 b).




Figure 2. Model fit to SARS-CoV-2 seroprevalence. a Age-specific seroprevalence. **b** Total seroprevalence. The data (dots and error bars) are based on the cross-sectional seroepidemiological survey (First National Serological Survey) conducted after the first pandemic wave [54]. **a** The violin shapes represent the marginal posterior distribution of the age-specific seroprevalence in the model. **b** The black line and the gray shaded region show the median total seroprevalence and 95% credible intervals. The uncertainty in the model is based on 2,000 parameter samples from the posterior distribution. The total seroprevalence refers to population older than 1 year [54].

85 Time-varying contact patterns and effective reproduction number

86 We estimated how age-specific contact rates in the population changed due to control measures as the pandemic
87 developed. These contact rates denote the average number of transmission-relevant contacts per day a person in
88 a given age category has with persons in other age categories. We further calculated the time-dependent effective
89 reproduction number, $R_e(t)$, defined as the average number of secondary infections caused by one infectious indi-
90 vidual in the population with age-specific contact patterns and age-specific seroprevalence at time t . $R_e(t) < 1$
91 signifies the control of the pandemic with possibly some of control measures in place. The full control of COVID-19
92 is achieved when $R_e(t) < 1$ and the contact rates in the population are restored to the pre-pandemic level.

93 Our findings are summarized in Figure 3, where we show the total daily hospitalizations (Figure 3 a), the average
94 (over all ages) number of daily contacts in the population (Figure 3 b) and $R_e(t)$ (Figure 3 c) evaluated bi-weekly
95 in the period from 26 February 2020 till 15 January 2021. The green vertical lines indicate the estimated mid-point
96 transitions in the age-specific contact rates (see Methods). The pre-pandemic average number of daily contacts was
97 12.6. The estimated basic reproduction number (in the absence of control measures and with zero seroprevalence)




Figure 3. Estimated contact rate and effective reproduction number. **a** Total daily hospital admissions with COVID-19. **b** Average (over all ages) number of daily contacts in the population. **c** Effective reproduction number, $R_e(t)$. The average daily contacts and R_e were evaluated once every two weeks. The green vertical lines indicate the estimated mid-point transitions in the age-specific contact rates. The red horizontal line denotes $R_e = 1$. The hospitalization data are shown as red dots. The black solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals.

98 was 2.20 (95%CrI 1.97–2.56). The control measures introduced during the first wave in spring 2020 reduced the
 99 number of contacts to 4.2 (95%CrI 3.3–5.0) and R_e to 0.69 (95%CrI 0.64–0.75). After some of these measures were
 100 lifted, the number of contacts increased to 5.9 (95%CrI 5.1–6.6) and R_e increased to almost 1 and stayed nearly
 101 constant throughout summer 2020. At the start of the second wave in autumn 2020 that followed the opening of
 102 schools and the associated changes in the contact patterns of the rest of the population, the average number of
 103 contacts further increased to about 7.6 (95%CrI 6.7–8.3) and R_e to 1.24 (95%CrI 1.21–1.28). The reinforcement of
 104 measures during the second wave could only reduce R_e to 0.89 (95%CrI 0.86–0.99) as compared to R_e of 0.69 after
 105 more severe measures introduced during the first wave. Finally, the increased activity of the population around
 106 Christmas and the New Year 2021 initiated the third wave in January 2021.

Table 1. The Portuguese vaccination plan.

Category	Age (years)	Vaccination period	Persons
Phase 1			937,361
Healthcare workers (HCW)	20 – 65	27 Dec 2020 – 28 Feb 2021	199,708
Long-term care facilities (LTCF)		01 Jan 2021 – 28 Feb 2021	148,119
Residents	65+		86,982
Staff	20 – 65		61,138
Risk Group 1	50+	01 Feb 2021 – 30 Apr 2021	513,634
Cardiac insufficiency			207,571
Coronary heart disease			169,265
Renal insufficiency			8,201
Chronic obstructive pulmonary disease (COPD)			128,597
First response professionals (FRP) (firemen, police, military etc.)	20 – 65	01 Feb 2021 – 30 Apr 2021	75,900
Phase 2			3,333,191
Persons with or without morbidities unvaccinated before*	65+	01 May 2021 – 31 Jul 2021	1,873,349
Risk Group 2	50 – 65	01 May 2021 – 31 Jul 2021	1,459,842
Diabetes			222,864
Neoplasm			114,246
Hepatic insufficiency			93,004
Chronic kidney disease			4,222
Obesity			392,959
High blood pressure			632,547
Phase 3			6,529,448
Remaining persons (excluding children)**	20 – 65	01 Aug 2021 – 31 Dec 2021	6,529,448
Total*			10,800,000

*The Portuguese vaccination plan assumes that all persons in the population will be vaccinated with a two-dose vaccine schedule. In the model, the maximum vaccination coverage in any age group is 90%. **According to the current guidelines, persons under 18 years old are not eligible for vaccination. In the model, we assumed that the age group of 0 to 20 years old is not vaccinated.

107 Vaccination rollout

108 We implemented the rollout of vaccination against SARS-CoV-2 as set out by the Directorate-General of Health —
109 a division of Portuguese Ministry of Health concerned with public health (Table 1). The mass vaccination started
110 on 27 December 2020, is planned to proceed in three phases that will cover the whole population of Portugal
111 by 31 December 2021. In the model, we made several simplifying assumptions regarding vaccination, i.e. 1) at
112 most 90% of each age group will be vaccinated (as supported by the survey conducted between 23 January and 5
113 February 2021 on the willingness to get vaccinated where the percentage of the Portuguese residents who want to get
114 vaccinated exceeds 95% [55]) except for persons under 20 years of age (as supported by the current guidelines on the
115 ineligibility for vaccination of persons under 18 years of age); 2) the distributed vaccine is by BioNTech/Pfizer brand
116 (as supported by the recent ECDC vaccination data for Portugal where 96% of vaccine doses distributed up until
117 February 21, 2021 are by BioNTech/Pfizer); 3) vaccination is modelled as a single event that immediately confers
118 protection equivalent to two vaccine doses; 4) we considered an infection-blocking vaccine and formulated optimistic
119 (main results) and pessimistic (sensitivity analyses) assumptions for vaccine efficacies in reducing infection, disease
120 and severe disease; 5) there is no waning of protection against (re-)infection after natural infection and vaccination.
121 More details of the vaccination model are given in Methods.

122 We used the rollout schedule (Table 1) and data (Figure 4 a) on the age distribution of morbidities among the
123 Portuguese residents and age distribution of prioritized vaccination categories (e.g., healthcare workers, long-term




Figure 4. Vaccination rollout schedule. **a** Age distribution of vaccination categories. **b** Total vaccination rate (number of persons vaccinated per day, black line) and proportions of vaccination rate attributable to ages [0,20) (blue), [20,60) (yellow) and 60+ (red). The gray vertical lines in **b** indicate the starting dates for different vaccination phases (Table 1). The age-specific vaccination rates are given in Figure S3.




Figure 5. Vaccination coverage during the vaccination rollout. **a** Age-specific coverage (percentage of vaccinated persons per age group). **b** Total vaccination coverage (percentage of vaccinated persons in the population). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1). The coverages for ages [20,30), [30,40), and [40,50) are equal (see Figure S4 for the absolute numbers of vaccinated persons). The coverage for ages [0,20) is zero. The ECDC vaccination rollout data in **b** are shown as red (1 dose) and blue (2 doses) dots.

124 care facilities staff and residents etc.) to calculate age-specific vaccination rates (number of persons in a given
125 age group vaccinated per day) as the vaccination programme progresses (Figure 4 b; see Figure S3 for detailed
126 information). The vaccination rate refers to vaccination with two vaccine doses. The maximum vaccination coverage
127 of 90% is projected to be reached in the following order (Figure 5 a): 80+ (29 June 2021), [60,80) (20 July–23 July
128 2021), [50,60) (29 August 2021) and [20,50) (16 November 2021) (see Figure S4 for absolute numbers of vaccinated
129 persons). The total coverage in the population will increase to 9%/38%/73% (maximum coverage) by 1 May/1
130 August/16 November 2021 (Figure 4 b). The ECDC vaccination rollout data for Portugal agree well with these
131 projections.

132 Scenarios for relaxation of control measures

133 To account for the epidemiological situation in Portugal between mid-January and mid-March 2021 [51], we modeled
134 the third wave of hospitalizations that was curbed by the substantial reinforcement of measures similar to those
135 implemented during the first wave in spring 2020. We also modelled an increase in the transmissibility of the virus due
136 to the rapid spread of B.1.1.7. variant in Portugal. The situation in mid-march 2021 is then described by the average
137 number of daily contacts of 4.2, R_e of 0.67 and the circulating variant that is 50% more transmissible [5–7] than
138 the original variant that was dominant in Portugal until December 2020. Starting from this situation, we generated
139 scenarios for relaxation of control measures as follows (Figure 6): Scenario 1) lifting all measures so that contact
140 rates in the population return to the pre-pandemic level (average rate of 12.6 contacts/day); Scenario 2) partial
141 lifting of measures that increases contact rates to the level of September-October 2020 (7.6 contacts/day); Scenario
142 3) partial lifting of measures that increases contact rates to the level of June-August 2020 (5.9 contacts/day). In
143 accordance with the plan of the Portuguese government to alleviate some of the current measures in spring 2021
144 and to make the scenarios comparable, we used the same mid-point (1 April 2021) and the same speed of transition
145 between the contact levels (10 days).

146 The comparative analysis of Scenarios 1, 2, and 3 is shown in Figure 6. The model predicts that lifting all measures
147 (Scenario 1; Figure 6 a-d) launches a fourth wave that is significantly larger than the previous waves, resulting in
148 58,226 cumulative hospitalizations between 1 April and 1 January 2022 (Figure 6 a). R_e increases sharply from
149 0.67 on 23 March 2021 to 2.03 two weeks later (Figure 6 c) which is very close to the basic reproduction number of
150 2.20 at the start of the pandemic. The full control over COVID-19 is reached on 18 May 2021 when R_e drops below
151 1 and the contact rates are the pre-pandemic level (Figure 6 b). At this threshold, 60% of the population acquired
152 protection after natural infection and only 10% are protected after vaccination (Figure 6 d). Relaxing measures
153 according to Scenario 2 (Figure 6 e-h) initiates a new pandemic wave too, albeit smaller in magnitude than Scenario
154 1 (8,975 hospitalizations between 1 April and 1 January 2022; Figure 6 e). In this case, R_e becomes smaller than
155 1 on 29 June 2021 (Figure 6 g) but the measures have to be kept in place (Figure 6 f) to control the spread. The
156 increase of contact rates to the level of June-August 2020 (Scenario 3; Figure 6 i-l), however, does not lead to a rise




Figure 6. Scenarios for relaxation of control measures. **a-d** Lifting all measures so that contact rates in the population return to the pre-pandemic level. **e-h** Partial lifting of measures so that contact rates increase to the level of September-October 2020. **i-l** Partial lifting of measures so that contact rates increase to the level of June-August 2020. The blue vertical lines indicate the mid-point of the transition (1 April 2020). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1). The red horizontal line denotes $R_e = 1$. The hospitalization data are shown as red dots. The thick solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals.

157 in hospitalizations (Figure 6 i) because R_e stays below 1 (Figure 6 k) but, like in Scenario 2, the measures have to
 158 continue until sufficient number of people acquire protection by vaccination to relax them completely.
 159 In addition, we explored Scenario 4 (Figure 7) where measures are relaxed in a step-wise manner so that contact
 160 rates first rise to the level of June-August 2020 (Step 1, Scenario 3), then to the level of September-October 2020
 161 (Step 2, Scenario 2) and, finally, to the pre-pandemic level (Step 3, Scenario 1) (Figure 7 b). The mid-points of
 162 transitions were 1 April, 1 June and 1 October 2021 (blue vertical lines in Figure 7) and the relaxation speed of 10
 163 days was used for all transitions. In this scenario, additional waves can be prevented altogether and hospitalizations
 164 stay at the level comparable to that in summer 2020 when the epidemic activity was low (Figure 7 a). Interestingly,
 165 Step 2 (1 June) and Step 3 (1 October) increase R_e above 1 (Figure 7 c) leading to waves of infections (Figure S5)




Figure 7. Sequential relaxation of control measures. This scenario consists of sequential relaxation of measures so that the contact rates increase, in sequence, to the level of June-August 2020, of September-October 2020 and the pre-pandemic level. The blue vertical lines indicate the mid-points of these transitions (1 April, 1 June, 1 October). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1). The red horizontal line denotes $R_e = 1$. The hospitalization data are shown as red dots. The thick solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals.

166 but a large increase in hospitalizations is not observed because a substantial proportion of the vulnerable population
 167 has been vaccinated (Figure 5). The full control of the pandemic ($R_e(t) < 1$ and pre-pandemic contact rates) is
 168 reached on 8 February 2022 (Figure 7 c) when 36% of the population are protected after natural infection, 48%
 169 after vaccination, and 17% stay unprotected (Figure 7 d). This is drastically different from Scenario 1, where the
 170 control was reached mainly due to protection through natural infection (60%), and the minority was protected by
 171 vaccination (10%).

172 Finally, we would like to stress that for demonstration purposes the timings of Steps 2 and 3 in Scenario 4 have
 173 been intentionally chosen so that the epidemic activity (i.e., the number of hospital admissions) in 2021 is similar
 174 to that in summer 2020. The premature relaxation of measures can still lead to new waves of hospitalizations. We
 175 demonstrate this in Figure S6 where Step 3 occurs on 1 August instead of 1 October 2021. Similarly, the results
 176 presented for Scenario 4 (and other scenarios as well) are the most optimistic in terms of projected hospitalizations
 177 and get worse for a pessimistic set of vaccine efficacies or if individuals return to pre-pandemic contact rates
 178 immediately upon getting vaccinated (see Figure S7).

179 Discussion

180 In this study, we used an age-structured model for SARS-CoV-2 transmission to generate several scenarios for
181 relaxation of control measures during the ongoing vaccination rollout in Portugal. In agreement with the plans
182 of the Portuguese government, the mid-point of easing of measures is April 2021. Our analyses demonstrate that
183 vaccination alone, if rolled out according to the national vaccination schedule, is likely to be insufficient to control
184 the Portuguese pandemic when control measures are significantly alleviated in April 2021. Returning to the pre-
185 pandemic lifestyle already in spring 2021 is the worst-case scenario that would be detrimental for the healthcare
186 system. Even for the most optimistic model assumptions, this scenario would result in a wave of hospitalizations
187 several orders of magnitude larger than the three previous waves. Relaxing measures to the same extent as in
188 autumn 2020 would lead to somewhat smaller wave (as compared to the worst-case scenario and even to the third
189 wave that actually occurred) that would, nonetheless, present a significant burden for the national healthcare.
190 These findings are qualitatively similar to those in modeling studies for China [28] and the UK [26, 27], but the
191 quantitative comparison is not possible because of different settings and contexts in which those studies were
192 conducted. Additional waves could be prevented altogether if measures in spring 2021 are relaxed to the same
193 extent as in summer 2020 or in a step-wise manner throughout 2021.

194 The point at which the pandemic is brought under full control ($R_e(t) < 1$ and pre-pandemic contact patterns)
195 depends on the amount of protection in the population acquired through a combination of natural infection and
196 vaccination. Gaining the control quickly (by mid-May 2021) occurs mainly through protection by natural infection
197 (60% of the population) while the minority (10%) would be protected by vaccination. As mentioned above, this
198 worst-case scenario is, obviously, undesirable and is not very much different from letting the pandemic develop
199 without any control measures. In the gradual relaxation scenario, achieving control takes more than one year
200 since the start of vaccination rollout, but almost 50% of the population are protected by vaccination and a smaller
201 proportion (35%) have experienced SARS-CoV-2 by that point. Alternative to these scenarios would be accelerating
202 the vaccination campaign so that vaccination coverage increases faster than initially projected and confirmed by
203 the ECDC vaccination rollout data [2]. However, it is not clear whether this option is viable for Portugal given the
204 current shortage for COVID-19 vaccines.

205 A strength of our analyses is that we calculate the effective reproduction number using the estimated current levels
206 of age-specific seroprevalence and vaccination coverage in the population instead of reducing the value of R_e at
207 the beginning of the pandemic homogeneously across age groups as it is done in e.g. the study for China [28].
208 Another strength is that, unlike this study [28] and the studies for the UK [26, 27], the parameters of our model
209 are statistically evaluated to match the course of the Portuguese pandemic as reflected by age-specific hospital
210 admissions and age-specific seroprevalence [54]. In addition, our fitting procedure allows for estimation of temporal
211 changes in age-dependent contact patterns as a response to prior control measures during this pandemic. Therefore,
212 instead of modeling specific relaxation policies, that are notoriously hard to implement in mechanistic transmission

213 models, we model several scenarios using the estimated contact structure after relaxation of measures in summer
214 and autumn 2020.

215 In light of these past measures, our findings are easy to interpret and contain an important message for local
216 policymakers. School opening is thought to be the main driver of the changes observed in autumn 2020, although
217 an increase in socializing indoors in general caused by weather alone must also have played a role. If the relaxation
218 planned for April 2021 includes school reopening in full after Easter and resuming indoor service in restaurants and
219 bars, then it is very likely that the average contact rate in the population will reach levels very similar to those
220 in autumn 2020. As a consequence, this might lead to a new wave of hospitalizations as illustrated in Scenario
221 2. On the bright side, according to our analysis the goal of Scenario 3, in which major waves are avoided, seems
222 well within reach, given the light control measures that were in place during summer 2020. Combining these with
223 some additional limitations of indoor social activities and online classes for secondary school students could help to
224 replicate the average contact rate of summer 2020, compensating for opening of elementary schools.

225 As any model, our model has limitations. An important one is that protection against (re-)infection after natural
226 infection and vaccination is permanent over the time-scale of our analyses (almost two years). This frequently
227 used assumption [26–28, 44, 47] leads to that in our model, theoretically, SARS-CoV-2 can be eliminated from the
228 population. However, as we discussed recently [56] and as addressed in several conceptual modeling studies [57–59],
229 accumulating evidence suggests that after the initial pandemic phase SARS-CoV-2 is likely to be transitioning to
230 endemicity and continued circulation. Specifically, recent data from individual-level studies point to that detectable
231 levels of antibodies to SARS-CoV-2 providing immunity against reinfection can wane on the time scale of a few
232 months to few years following exposure, as shown by our group [60] and corroborated with findings of other
233 studies [61–63]. However, the immunity to SARS-CoV-2 depending on a combination of B- and T-cell-mediated
234 responses elicited during primary SARS-CoV-2 infection could reduce susceptibility to and infectiousness of the
235 following infections and offer protection against severe disease, i.e. COVID-19 [64]. The estimation of the model
236 parameters and evaluation of relaxation strategies in light of waning of sterilizing immunity lies outside the scope
237 of our study but it should be addressed in future work when convincing data on reinfections in unvaccinated and
238 vaccinated individuals become available.

239 Another limitation is that our results are based on early data on the efficacy in clinical trials and real-world
240 effectiveness of the Pfizer-BioNTech vaccine [15, 18–22]. We also assume that vaccine efficacy against the B.1.1.7
241 variant circulating in Portugal is the same as the efficacy reported from studies conducted in other locations as
242 supported by the recent study among working age adults in England [22], where the dominant variant in circulation
243 was B.1.1.7. This study demonstrated that effectiveness of the Pfizer-BioNTech vaccine against symptomatic and
244 asymptomatic infection is 86% seven days after two doses [22]. However, SARS-CoV-2 mass vaccination programmes
245 and prolonged control measures can generate selection pressure leading to viral adaptation, antigenic divergence
246 or vaccine escape. Viral adaptations may contribute to decreasing efficacy of existing vaccines via faster waning

247 of sterilizing immunity. For example, recent experiments demonstrate that the South African variant B.1.351
248 shows reduced neutralizing antibody binding increasing the prospects of reinfection and hampering the efficacy of
249 spike-based vaccines [65]. This will need consideration in vaccine development and evaluation of future vaccination
250 programmes and relaxation scenarios in mathematical transmission models. A possible case where an antigenic
251 escape variant caused a resurgence of COVID-19 despite high population-level seroprevalence was observed in
252 Manaus, Brazil [30].

253 To summarize, our study provides timely input into the discussion about the pandemic response during the vacci-
254 nation rollout in Portugal. Our analyses suggest that the pressing need to restart socioeconomic activities might
255 lead to new waves of hospitalizations in 2021 and that substantial measures prove necessary to control COVID-19
256 throughout 2021. More favourable scenarios that help to avoid future waves include relaxation of measures as in
257 summer 2020 or a step-wise approach when measures are relaxed gradually until the end of 2021.

258 **Methods**

259 **Overview**

260 The transmission model was calibrated using a combination of behavioral, surveillance and demographic data for
261 Portugal. Parameter estimates were obtained from the model fit to (i) age-stratified COVID-19 hospitalization
262 data ($n = 28,482$) in the period from 26 February 2020 till 15 January 2021 and (ii) cross-sectional age-stratified
263 SARS-CoV-2 seroprevalence data ($n = 2,301$) assessed from 21 May 2020 till 8 July 2020 [54]. The model was
264 further used to investigate relaxation scenarios as vaccination is rolled out in 2021.

265 **Data**

266 The hospitalization data included $n = 28,482$ COVID-19 hospitalizations longer than 24 hours by date of admission
267 and stratified by age during the period of 325 days following the first official case in Portugal (2 March 2020). The
268 data was padded with 5 days without hospitalizations (from 26 February till 1 March 2020) to allow for the
269 estimation of the number of infected individuals at the start of the pandemic. The hospitalization data spanned the
270 first wave in spring 2020, relatively low epidemic activity in summer 2020, the second wave that started in autumn
271 2020 till mid-December 2020 and the third wave that started in mid-December 2020 and was still ongoing on 15
272 January 2021. The data source for hospital data was the Central Administration of the Health System and the
273 Shared Services of the Ministry of Health, covering all public hospitals in Portugal receiving COVID-19 patients.
274 Since early in the pandemic, Portugal adopted a policy of hospitalizing only patients who did not gather minimum
275 conditions for being followed at the domicile, either due to clinical or sanitary conditions. This policy has not
276 changed during the course of the pandemic.

277 The SARS-CoV-2 seroprevalence data was based on the First National Serological Survey (ISNCOVID-19) in

278 Portugal in May/July 2020 [54]. This cross-sectional seroepidemiological survey was conducted on a sample of
 279 $n = 2,301$ Portuguese residents, aged 1 year or older, after the first wave. The survey sample was selected using a
 280 two-stage stratified non-probability sampling design (quota sampling) [54]. SARS-CoV-2 IgM and IgG antibodies
 281 were measured in serum samples by enzyme-linked immunosorbent assay. Further details of the study are given
 282 in [54]. For the model fitting, we used the sample size, the number of positive samples and 95% confidence intervals
 283 stratified by age group reported in [54].

284 The demographic composition of the Portuguese residents was taken for 2019 from the Contemporary Portugal
 285 Database (Pordata) [66]. The vaccination analyses made use of the vaccination programme (Table 1), as defined by
 286 the Directorate-General of Health [51]. The programme defines vaccine uptake prioritization by age and morbidities
 287 and runs in three phases from 27 December 2020 till 31 December 2021. The age distribution of morbidities in the
 288 Portuguese population was extracted from the Shared Services of the Ministry of Health on the basis of ICPC-2
 289 (International Classification of Primary Care) codes (Table S1). The vaccination rollout data for Portugal was
 290 taken from the ECDC website.

291 The baseline (pre-pandemic) contact matrices for transmission-relevant contacts for Portugal were taken from the
 292 recent study by Mistry and colleagues [67]. The contact matrix for Portugal after the introduction of measures to
 293 control the first wave of hospitalizations (April 2020) was inferred using the contact matrix for the Netherlands
 294 based on a cross-sectional survey carried out in April 2020 (PIENTER Corona study) [68].




Figure 8. Schematic of the transmission model. Gray arrows show epidemiological transitions. Red dashed boxes indicate compartments contributing to the forces of infection. The model is age-structured and involves an extended SEIR-type framework. Vaccinated persons may experience behavior compensation post-vaccination modelled as a return to pre-pandemic contact rates among vaccinated persons as compared to unvaccinated persons who may continue to have reduced contact rates due to control measures. The vaccine has three effects: (i) reduction in susceptibility of vaccinated relative to unvaccinated (VE_S); (ii) reduction in infectivity of vaccinated relative to unvaccinated (VE_I , not shown); (iii) reduction in hospitalization rate of vaccinated relative to unvaccinated (VE_H).

295 **Transmission model**

296 We extended an age-stratified SARS-CoV-2 transmission model from [43] to include vaccination (Figure 8). The
297 model has susceptible-exposed-infectious-recovered structure, whereby susceptible persons (S) may become latently
298 infected (E) before progressing to become infectious (I). Infectious persons either get hospitalized (H) or recover
299 without hospitalization (R). Disease-related mortality and discharge from the hospital are not explicitly modeled.
300 Therefore, the H -compartment contains the cumulative number of persons who experience severe symptoms and
301 recover (or die) after admission to the hospital. Similarly, the R -compartment contains the cumulative number
302 of persons who recover after having mild or no symptoms. The force of infection is given by a weighted sum of
303 the fraction of the infectious population in different age groups (red dashed boxes in Figure 8). We consider a
304 stable population and thus do not include natural birth and death processes. The contact rates, forces of infection,
305 susceptibilities and hospitalization rates are age-specific.

306 In line with the current guidelines, we assume that vaccine can be delivered to all people independently from their
307 disease history with the exception of those who might be currently infectious (I -compartment). Not vaccinating in-
308 fectious compartment implies that vaccine is not given to asymptomatic persons but these represent a small fraction
309 of the population at any given time. We also vaccinate the H -compartment as this compartment comprises everyone
310 who has ever been admitted to hospital. Whilst this assumption means that the currently hospitalized persons are
311 vaccinated too, their number is very small compared to the total number of people in the H -compartment. The
312 vaccine has three mechanisms of action: (i) reducing susceptibility (VE_S); (ii) reducing infectivity (VE_I); (iii)
313 reducing hospitalization rate (VE_H). The vaccine has no effect in persons who recovered from natural infection (R
314 and H compartments). We assume that protection after vaccination is achieved immediately and is equivalent to
315 two vaccine doses, and that the duration of protection after both natural infection and vaccination is about two
316 years (time horizon of our analyses). Finally, we allow for behavior compensation post-vaccination modelled as
317 a return to pre-pandemic contact rates among vaccinated persons as compared to unvaccinated persons who may
318 continue to have reduced contact rates due to control measures. This is reflected in generally different forces of
319 infection for unvaccinated and vaccinated persons. The full description of the model parameters is given in Tables
320 [S2](#) and [S4](#).

321 **Model equations**

322 The model was implemented in Mathematica 10.0.2.0 using a system of ordinary differential equations for the
323 number of persons in different compartments shown in Figure 1. The transmission model was stratified into $n = 10$
324 age groups: $[0, 5)$, $[5, 10)$, $[10, 20)$, $[20, 30)$, $[30, 40)$, $[40, 50)$, $[50, 60)$, $[60, 70)$, $[70, 80)$, $80+$.

325 The equations for the numbers of unvaccinated persons in age group k , $k = 1, \dots, n$, who are susceptible (S_k),

326 exposed (E_k), infectious (I_k), recovered (R_k) and hospitalized (H_k) read as follows

$$\begin{aligned}
 327 \quad \frac{dS_k(t)}{dt} &= -\beta_k \lambda_k(t) S_k(t) - \frac{r_k S_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, & (1) \\
 328 \quad \frac{dE_k(t)}{dt} &= \beta_k \lambda_k(t) S_k(t) - \alpha E_k(t) - \frac{r_k E_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\
 329 \quad \frac{dI_k(t)}{dt} &= \alpha E_k(t) - (\gamma + \nu_k) I_k(t), \\
 330 \quad \frac{dR_k(t)}{dt} &= \gamma I_k(t) - \frac{r_k R_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\
 331 \quad \frac{dH_k(t)}{dt} &= \nu_k I_k(t) - \frac{r_k H_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}.
 \end{aligned}$$

332 The equations for the numbers of vaccinated persons in age group k who are vaccinated susceptible (S_k^V), exposed
 333 (E_k^V), infectious (I_k^V), recovered (R_k^V) and hospitalized (H_k^V) are given by

$$\begin{aligned}
 334 \quad \frac{dS_k^V(t)}{dt} &= -\beta_k(1 - VE_S) \lambda_k^V(t) S_k^V(t) + \frac{r_k S_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, & (2) \\
 335 \quad \frac{dE_k^V(t)}{dt} &= \beta_k(1 - VE_S) \lambda_k^V(t) S_k^V(t) - \alpha E_k^V(t) + \frac{r_k E_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\
 336 \quad \frac{dI_k^V(t)}{dt} &= \alpha E_k^V(t) - (\gamma + \nu_k(1 - VE_H)) I_k^V(t), \\
 337 \quad \frac{dR_k^V(t)}{dt} &= \gamma I_k^V(t) + \frac{r_k R_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\
 338 \quad \frac{dH_k^V(t)}{dt} &= \nu_k(1 - VE_H) I_k^V(t) + \frac{r_k H_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}.
 \end{aligned}$$

339 Persons get vaccinated in S , E , R and H states. The vaccination rates r_k are age-specific. We denote the contact
 340 rate of an unvaccinated person in age group k with persons in age group l , $c_{kl}(t)$, and the contact rate of a vaccinated
 341 person in age group k with persons in age group l , $c_{kl}^V(t)$. The forces of infection for unvaccinated and vaccinated
 342 persons are given by

$$343 \quad \lambda_k(t) = \epsilon \sum_{l=1}^n c_{kl}(t) \frac{I_l(t) + (1 - VE_I) I_l^V(t)}{N_l}, \quad (3)$$

$$344 \quad \lambda_k^V(t) = \epsilon \sum_{l=1}^n c_{kl}^V(t) \frac{I_l(t) + (1 - VE_I) I_l^V(t)}{N_l}, \quad (4)$$

345 where N_k is the number of individuals in age group k , $N_k = S_k(t) + E_k(t) + I_k(t) + H_k(t) + R_k(t) + S_k^V(t) +$
 346 $E_k^V(t) + I_k^V(t) + R_k^V(t) + H_k^V(t)$. Note that Eqs. (3) and (4) imply that the entire population participates in the
 347 contact process including persons in the H -compartment but that H -persons are not infectious. This is based on
 348 the fact that the vast majority of people in the H -compartment are recovered after hospitalization, and a very small
 349 proportion is currently hospitalized. We assume that currently hospitalized persons continue to have contacts with
 350 the personnel and visitors but they cannot infect them because of the use of individual protective measures.

351 The initial condition for the model was $E_k(t=0) = I_k(t=0) = \frac{1}{2}\theta N_k$ and $S_k(t=0) = (1-\theta)N_k$, where $t=0$ is
 352 26 February 2020. The parameter θ denotes the initial fraction of the population that was infected (split equally
 353 between infectious and exposed). This parameter accounts for importation of new cases at the start of the pandemic
 354 and was estimated jointly with other parameters. Importation of cases was not implemented at later stages of the
 355 pandemic due to a large pool of infectious individuals within the country.

356 The rapid spread of B.1.1.7 variant, that is estimated to be about 50% more transmissible based on the data from
 357 England [5–7], fueled the third wave of hospitalizations in Portugal. The increasing dominance of this variant
 358 was modelled empirically as a gradual increase in the probably of transmission per contact by 50% as follows
 359 $\epsilon[1 + 0.5/(1 + e^{-K_0(t-t_{\text{data}})})]$, where ϵ and K_0 were estimated based on the data until 15 January 2021 (Figure S2)
 360 and t_{data} is the last date in the hospital admission data (15 January 2021).

361 Observation model and parameter estimation

362 To generate a set of plausible parameters and initial conditions for our projections, we fitted the model to hos-
 363 pitalization data and serological testing data, using a similar approach as before [43, 69]. We incorporated the
 364 transmission model, Eq. (1), in a Bayesian statistical model with likelihood function constructed as follows. Let
 365 $h_{k,m}$ denote the observed number of hospitalizations in age group k and day t_m . The expected number of hos-
 366 pitalizations during day t_m is approximately equal to $\bar{h}_{k,m} := \nu_k \cdot I_k(t_m)$. To account for reporting errors and
 367 heterogeneity in the hospitalization rate within age groups, we assume that $h_{k,m}$ has a negative-binomial distri-
 368 bution with mean $\bar{h}_{k,m}$ and variance $\bar{h}_{k,m} \cdot (1 + \bar{h}_{k,m}/\phi)$. The parameter ϕ determines the overdispersion of the
 369 reporting of hospitalizations. The hospitalization data were stratified into the ten age groups $[0, 5)$, $[5, 10)$, $[10, 20)$,
 370 $[20, 30)$, $[30, 40)$, $[40, 50)$, $[50, 60)$, $[60, 70)$, $[70, 80)$, $80+$.

371 The seroprevalence data were stratified into the five age groups $[1, 10)$, $[10, 20)$, $[20, 40)$, $[40, 60)$ and $60+$ [54]. Hence,
 372 for the hospitalization data and the transmission model, a finer age stratification is used than for the seroprevalence
 373 data. We assume that individuals in seroprevalence age group G_i^s were sampled from hospitalization age class G_k^h
 374 with probability p_{ik} proportional to the relative population size of G_k^h compared to G_i^s , i.e.

$$375 \quad p_{ik} = N_k/N_i^s, \quad \text{where} \quad N_i^s = \sum_{\ell: G_\ell^h \subseteq G_i^s} N_\ell. \quad (5)$$

376 As before [43], we assume that the seroprevalence data represents a random sample from each age group. Hence,
 377 the number of positive samples ℓ_i has a binomial distribution with population size L_i , equal to the total number
 378 of samples for age class i , and success probability q_i . The success probability is defined in terms of the fraction of
 379 susceptible individuals $S_k(T)$ at sampling time T and the probabilities p_{ik} :

$$380 \quad q_i = \sum_{k: G_k^h \subseteq G_i^s} (1 - S_k(T)/N_k) p_{ik} \quad (6)$$

381 To account for the fact that no children below the age of 1 year were included in the serology samples, we reduced
382 the population size N_1 with the size of the age group $[0, 1)$ (86,579 persons) in Eq. (6) and Eq. (5).

383 The prior distribution of the model is specified in Table S3. The model was fitted with Stan [70] in R 3.6.0 and R
384 Studio 1.3.1056. We used 4 parallel chains, each of length 1,000, with a warm-up period of 500, resulting in 2,000
385 samples from the posterior distribution. Convergence was assessed with the Gelman-Rubin \hat{R} -statistic, which was
386 close to 1 for all parameters. The estimated model parameters are shown in Figures S1 and S2.

387 Time-varying contact patterns

388 The contact patterns in the population varied with time due to introduction/reinforcement or relaxation of control
389 measures as follows: 0) introduction of measures to control the first pandemic wave (first lockdown, March 2020); 1)
390 relaxation of measures after the first wave was curbed (May 2020); 2) further relaxation of measures that included
391 school opening (September 2020); 3) reinforcement of measures to control the second wave (second lockdown,
392 November 2020); 4) relaxation of measures around Christmas 2020; 5) reinforcement of measures to control the
393 third wave (third lockdown, January 2021).

394 We denote $c_{kl}(t)$ the contact rate for a person in age group k ($k = 1, \dots, n$) with persons in age group l ($l = 1, \dots, n$)
395 at time t . The contact rate denotes the number of transmission-relevant contacts per day such as touching or having
396 a conversation with someone [67, 68]. Our fitting procedure allows to estimate $c_{kl}(t)$ by assuming that changes due
397 to control measures described in 0)-5) occur as a series of smooth transitions.

398 To describe the transition 0) from the baseline (pre-pandemic) contact rate b_{kl} to the contact rate after the first
399 lockdown a_{kl} we write down $c_{kl}(t)$ as a linear combination of contact rates b_{kl} and a_{kl} with coefficients constructed
400 using a logistic function $f_0(t) = 1 / (1 + e^{-K_0(t-t_0)})$ as follows

$$401 \quad c_{kl}(t) = [1 - f_0(t)]b_{kl} + f_0(t)\zeta a_{kl}. \quad (7)$$

402 The parameter K_0 of the logistic function describes the speed with which the first lockdown is enforced. The
403 parameter t_0 describes the mid-time of the introduction of the first lockdown. Note in Eq. 7 we introduced the
404 factor $\zeta \in [0, 1]$ to reflect that not all reported contacts after the first lockdown might be relevant for transmission,
405 for example, due to mask-wearing or physical distancing when a contact took place. Therefore, the baseline (pre-
406 pandemic) contact rates are described by the matrix b_{kl} , and the contact rates after the first lockdown are described
407 by the matrix ζa_{kl} .

408 The pre-pandemic matrix b_{kl} for Portugal was taken from [67] (Figure 9 a). The matrix after the first lockdown
409 a_{kl} was inferred using the contact matrix for the Netherlands based on a cross-sectional survey carried out in April
410 2020 (PIENTER Corona study) [68]. Since measures enforced during the first lockdown in the two countries were
411 similar (e.g., all schools were closed, all non-essential work was done from home etc.) we reduced the age-specific




Figure 9. Contact matrices. **a** Baseline (pre-pandemic) contact matrix. **b** Contact matrix after the introduction of measures in April 2020. **c** Average number of contacts for a person in a given age group. **d** Logistic functions describing transitions between contact matrices. Shown are f_0 (blue), f_1 (dark green), f_2 (light green), f_3 (orange), and f_4 (red) based on 50 samples from the posterior distribution.

412 contact rates for Portugal after the lockdown by the same percentage as it was observed in the Netherlands (Figure
 413 **9 b**). The resulting number of daily contacts for a person in given age group at baseline and after the lockdown
 414 in April 2020 is shown in Figure **9 c**. Like for the Netherlands [68], we observe larger reductions in contacts for
 415 children (due to school closure) and smaller reductions for elderly because most of their contacts were essential
 416 (e.g., with healthcare personnel or caretakers) and thus were not affected by the lockdown. The parameter ζ that
 417 multiplies the inferred matrix a_{kl} can account for discrepancies between the real and inferred matrix.
 418 To describe the contact rates after transitions 1)-4) have taken place, we assume that these can be written as a
 419 liner combination $u_i b_{kl} + (1 - u_i) \zeta a_{kl}$, $i = 1, \dots, 4$, where u_i is the proportion of time a person behaves as before
 420 the pandemic and $(1 - u_i)$ is, respectively, the proportion of time a person behaves as during the first lockdown.
 421 This contact structure can, therefore, interpolate between the first (most strict) lockdown and no measures in place
 422 at all. Since the third lockdown was similar to the first lockdown, the transition 5) was modelled as a return to
 423 the lockdown contact matrix ζb_{kl} . As before, the transitions between the contact rates during periods 1)-5) are
 424 modelled using logistic functions $f_i(t) = 1 / (1 + e^{-K_i(t-t_i)})$, where $i = 1, \dots, 5$. The general contact rate can
 425 therefore be written as

$$\begin{aligned}
 426 \quad c_{kl}(t) &= [1 - f_0(t)]b_{kl} + f_0(t)\zeta a_{kl}[1 - f_1(t)] + f_1(t)[u_1 b_{kl} + (1 - u_1)\zeta a_{kl}][1 - f_2(t)] \\
 427 &+ f_2(t)[u_2 b_{kl} + (1 - u_2)\zeta a_{kl}][1 - f_3(t)] + f_3(t)[u_3 b_{kl} + (1 - u_3)\zeta a_{kl}][1 - f_4(t)] \\
 428 &+ f_4(t)[u_4 b_{kl} + (1 - u_4)\zeta a_{kl}][1 - f_5(t)] + f_5(t)\zeta a_{kl}. \tag{8}
 \end{aligned}$$

429 All the parameters that describe $c_{kl}(t)$, except for the last transition 5) for which hospitalization data are not
 430 available, are estimated (Table S4). The estimates for these 15 parameters ζ , u_i ($i = 1, \dots, 4$), t_i ($i = 0, \dots, 4$) and
 431 K_i ($i = 0, \dots, 4$) are shown in Figure S2. The estimated logistic functions are plotted in Figure **9 d**.

432 In the main analyses (Figures 6 and 7), the contact rates for vaccinated persons were equal to those unvaccinated,
 433 $c_{kl}^V(t) = c_{kl}(t)$. In the sensitivity analyses (Figure S7), they were set to pre-pandemic contacts as follows, $c_{kl}^V(t) = b_{kl}$.
 434 The contact rate presented in Figures 3, 6 and 7 was the average contact rate in the population calculated as
 435 follows $\langle c(t) \rangle = \sum_{k=1}^n \sum_{l=1}^n c_{kl}(t) N_k / \sum_{k=1}^n N_k$. Note that this expression makes use of the fact that in the main analyses
 436 $c_{kl}^V(t) = c_{kl}(t)$.

437 The relaxation scenarios during the vaccination rollout are modelled as a transition from the contact rate described
 438 by Eq. (8) to the contact rate b_{kl} (Scenario 1); $u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$ (Scenario 2); $u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$ (Scenario 3);
 439 $u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$ (Scenario 4, Step 1); $u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$ (Scenario 4, Step 2); b_{kl} (Scenario 4, Step 3). The
 440 parameters of the logistic functions describing these transitions are specified in Table S4.

441 Time-varying effective reproduction number

442 The basic reproduction number, R_0 , is the average number of secondary infections caused by a single infectious
443 individual at the beginning of the epidemic in a disease-free, totally susceptible population. If $R_0 > 1$ the disease
444 will spread exponentially. If $R_0 < 1$ the number of infectious persons declines exponentially and the disease is not
445 able to spread. In general, R_0 depends on the type of virus but also on the contact patterns in the population.

446 When the disease has already spread and we have no longer a fully susceptible population but some part of the
447 population is immune due to natural infection or vaccination, the generalization of R_0 is given by the effective
448 reproduction number, $R_e(t)$. $R_e(t)$ depends on the type of virus, the level of population immunity and the contact
449 patterns in the population. The full control of the disease is achieved when $R_e(t) < 1$ and the contact rates in
450 the population are at their pre-pandemic levels, i.e., not anymore affected by control measures. A partial control
451 is achieved when $R_e(t) < 1$ but the contact rates have not been restored to their pre-pandemic levels yet as is
452 currently the case for SARS-CoV-2 in Portugal.

453 In a deterministic compartmental model such as the one employed here, the calculation of R_0 and $R_e(t)$ can be
454 performed using the next-generation matrix (NGM) method [71]. The starting point of the method is to calculate
455 the Jacobian \mathbf{J} of the equations for the latent (E_k, E_k^V) and infectious (I_k, I_k^V) age classes $k, k = 1, \dots, n$, isolated
456 from the full model given by Eqs. (1) and (2). The Jacobian \mathbf{J} is then evaluated at the disease-free equilibrium of
457 interest.

458 For R_0 calculation, the disease-free equilibrium is

$$459 \quad S_k^* = N_k, \quad S_k^{V*} = E_k^* = E_k^{V*} = I_k^* = I_k^{V*} = 0, \quad k = 1, \dots, n. \quad (9)$$

460 For $R_e(t)$ calculation with or without vaccination, the disease-free equilibrium is

$$461 \quad S_k^* = S_k(t), \quad S_k^{V*} = S_k^V(t), \quad E_k^* = E_k^{V*} = I_k^* = I_k^{V*} = 0, \quad r_k = 0, \quad k = 1, \dots, n, \quad (10)$$

462 where the time-dependent variables $S_k(t)$ and $S_k^V(t)$ are obtained from the solutions of the full model given by Eqs.
463 (1) and (2).

464 Following [71], the Jacobian \mathbf{J} may be recast as follows

$$465 \quad \mathbf{J} = \mathbf{T} + \mathbf{\Sigma}, \quad (11)$$

466 where the transmissions matrix \mathbf{T} contains the terms associated with the production of new infections, and the
467 transitions matrix $\mathbf{\Sigma}$ contains the terms associated with all other state changes. After performing this operation,

468 we construct a new matrix \mathbf{K}_L , called the large domain NGM [71], given by

$$469 \quad \mathbf{K}_L = -\mathbf{T}\boldsymbol{\Sigma}^{-1}. \quad (12)$$

470 The basic reproduction number R_0 at time $t = 0$ and the effective reproduction number $R_e(t)$ at any time t are given
471 by the spectral radius of \mathbf{K}_L which is the largest eigenvalue of \mathbf{K}_L . For the purpose of computing the spectral radius,
472 \mathbf{K}_L can be further reduced as detailed in [71]. The explicit expressions for matrices \mathbf{J} , \mathbf{T} , $\boldsymbol{\Sigma}$ and \mathbf{K}_L are given in the
473 Mathematica notebooks available in the GitHub repository, <https://github.com/lynxgav/COVID19-vaccination>.

474 Population immunity

475 The unprotected population was computed as the number of individuals in the fully susceptible compartment S
476 (Figure 8). The population protected by natural infection was computed as all individuals arriving into the infectious
477 compartment I , independently of whether these individuals will or will not be vaccinated later on. Recall, that in the
478 model vaccine has no effect in individuals who are recovered from natural infection and, therefore, the population
479 protected by vaccination grows slower than vaccination coverage. The population protected by vaccination was
480 computed as all individuals arriving into the compartments S^V and I^V due to vaccination.

481 Vaccine efficacies

482 Vaccine efficacies in reducing susceptibility (VE_S), infectivity (VE_I) and hospitalization rate (VE_H) were set using
483 initial data from clinical trials and real-word studies for the Pfizer-BioNTech vaccine [15, 18–22]. Important to note,
484 that the efficacies reported in all these studies are not conditioned on infection while they are in the models like
485 ours. For a more complete discussion on this topic, we refer the reader to the pedagogical work by Lipsitch and
486 Kahn [23] and the report for England by the Scientific Advisory Group for Emergencies [26].

487 The vaccine efficacy in reducing susceptibility (VE_S) was set based on vaccine efficacies and effectiveness against
488 infection ($VE_{\text{infection}}$) reported in clinical trials and real-word studies, i.e.

$$489 \quad VE_{\text{infection}} \equiv VE_S. \quad (13)$$

490 The vaccine efficacy in reducing infectivity (VE_I) was assumed to be the same as vaccine efficacy in reducing disease
491 conditioned on infection ($VE_{\text{disease|infection}}$), i.e. $VE_{\text{disease|infection}} \equiv VE_I$. $VE_{\text{disease|infection}}$ was calculated using
492 the efficacy against disease (VE_{disease}) reported in clinical trials as follows

$$493 \quad VE_{\text{disease}} = VE_{\text{infection}} + (1 - VE_{\text{infection}})VE_{\text{disease|infection}}. \quad (14)$$

494 The vaccine efficacy in reducing hospitalization rate (VE_H) is equal to vaccine efficacy against severe disease con-

ditioned on disease ($VE_{\text{severe disease}|\text{disease}}$), i.e. $VE_{\text{severe disease}|\text{disease}} \equiv VE_H$. $VE_{\text{severe disease}|\text{disease}}$ was calculated using the vaccine efficacy against severe disease ($VE_{\text{severe disease}}$) reported in trials as follows

$$VE_{\text{severe disease}} = VE_{\text{infection}} + (1 - VE_{\text{infection}})VE_{\text{disease}|\text{infection}} + (1 - VE_{\text{infection}})(1 - VE_{\text{disease}|\text{infection}})VE_{\text{severe disease}|\text{disease}}. \quad (15)$$

We used an optimistic and a pessimistic set of vaccine efficacies for VE_S , VE_I and VE_H (Table S2) based on the range of values for $VE_{\text{infection}}$, VE_{disease} , and $VE_{\text{severe disease}}$ reported in the literature [15, 18–22]. For the optimistic set explored in the main analyses (Figures 6 and 7), we used $VE_{\text{infection}} = 94\%$, $VE_{\text{disease}} = 94\%$, and $VE_{\text{severe disease}} = 98\%$ (corresponding to $VE_S = 94\%$, $VE_I = 0\%$, and $VE_H = 67\%$) [15, 18, 19, 21, 22, 26]. For the pessimistic set explored in sensitivity analyses (Figure S7), we used $VE_{\text{infection}} = 55\%$, $VE_{\text{disease}} = 55\%$, and $VE_{\text{severe disease}} = 55\%$ (corresponding to $VE_S = 55\%$, $VE_I = 0\%$, and $VE_H = 0\%$) [19, 20, 26]. Other efficacies reported in the literature for the Pfizer-BioNTech vaccine and other existing vaccines fall in between the optimistic and pessimistic values we used. This broad range of values is also relevant in case the market share of different vaccine brands in Portugal gets changed throughout 2021.

Data availability

The data used in this study are publicly available at <https://github.com/lynxgav/COVID19-vaccination>.

Code availability

The codes reproducing the results of this study are publicly available at <https://github.com/lynxgav/COVID19-vaccination>.

References

- [1] Coronavirus (COVID-19) vaccinations; 2021. Available from: <https://ourworldindata.org/covid-vaccinations>.
- [2] The European Centre for Disease Prevention and Control COVID-19 Vaccine Tracker; 2021. Available from: <https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>.
- [3] Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants. *Cell*. 2021;184(5):1127–1132. doi:10.1016/j.cell.2021.01.044.

- 521 [4] The European Centre for Disease Prevention and Control Risk Assessment: Risk related
522 to the spread of new SARS-CoV-2 variants of concern in the EU/EEA first update ;
523 21 January, 2021. Available from: [https://www.ecdc.europa.eu/en/publications-data/
524 covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update).
- 525 [5] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility
526 and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021;doi:10.1126/science.abg3055.
- 527 [6] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-
528 CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv*.
529 2021;doi:10.1101/2020.12.30.20249034.
- 530 [7] Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. The effect of SARS-CoV-2 variant
531 B.1.1.7 on symptomatology, re-infection and transmissibility. *medRxiv*. 2021;doi:10.1101/2021.01.28.21250680.
- 532 [8] Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but
533 do have immune escape. *Cell*. 2021;doi:https://doi.org/10.1016/j.cell.2021.02.042.
- 534 [9] Priesemann V, Balling R, Brinkmann MM, Ciesek S, Czypionka T, Eckerle I, et al. An action plan
535 for pan-European defence against new SARS-CoV-2 variants. *The Lancet*. 2021;397(10273):469–470.
536 doi:10.1016/S0140-6736(21)00150-1.
- 537 [10] Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S, et al. Increased mortality in community-
538 tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature*. 2021;doi:10.1038/s41586-021-03426-1.
- 539 [11] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in
540 patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ*. 2021;372.
541 doi:10.1136/bmj.n579.
- 542 [12] The European Centre for Disease Prevention and Control Risk assessment: SARS-CoV-2 -
543 increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th up-
544 date; 15 February, 2021. Available from: [https://www.ecdc.europa.eu/en/publications-data/
545 covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021).
- 546 [13] Gozzi N, Chinazzi M, Davis JT, Mu K, y Piontti AP, Ajelli M, et al. Estimating the spread-
547 ing and dominance of SARS-CoV-2 VOC 202012/01 (lineage B.1.1.7) across Europe. *medRxiv*.
548 2021;doi:10.1101/2021.02.22.21252235.
- 549 [14] European Medicines Agency COVID-19 vaccines: authorised; 2021. Available from: [https://www.ema.
550 europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/
551 treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised).

- 552 [15] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of
553 the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*. 2020;383(27):2603–2615.
554 doi:10.1056/NEJMoa2034577.
- 555 [16] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the
556 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised con-
557 trolled trials in Brazil, South Africa, and the UK. *The Lancet*. 2021;397(10269):99–111. doi:10.1016/S0140-
558 6736(20)32661-1.
- 559 [17] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273
560 SARS-CoV-2 Vaccine. *New England Journal of Medicine*. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
- 561 [18] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-
562 19 Vaccine in a Nationwide Mass Vaccination Setting. *New England Journal of Medicine*. 0;0(0):null.
563 doi:10.1056/NEJMoa2101765.
- 564 [19] Moustsen-Helms IR, Emborg HD, Nielsen J, Nielsen KF, Krause TG, Mølbak K, et al. Vaccine effectiveness
565 after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and
566 healthcare workers – a Danish cohort study. *medRxiv*. 2021;doi:10.1101/2021.03.08.21252200.
- 567 [20] Chodick G, Tene L, Patalon T, Gazit S, Tov AB, Cohen D, et al. The effectiveness of the first dose of
568 BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence.
569 *medRxiv*. 2021;doi:10.1101/2021.01.27.21250612.
- 570 [21] Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public
571 Health Impact of Vaccination One Year After Pandemic Declared; 2021. Available from: [https://www.
572 businesswire.com/news/home/20210311005482/en/](https://www.businesswire.com/news/home/20210311005482/en/).
- 573 [22] Hall, Victoria Jane and Foulkes, Sarah and Saei, Ayoub and Andrews, Nick and Oguti, Blanche and Charlett,
574 Andre and Wellington, Edgar and Stowe, Julia and Gillson, Natalie and Atti, Ana and Islam, Jasmin and
575 Karagiannis, Ioannis and Munro, Katie and Khawam, Jameel and Group, The SIREN Study and Chand,
576 Meera A and Brown, Colin and Ramsay, Mary E and Bernal, Jamie Lopez and Hopkins, Susan. Effectiveness
577 of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in
578 England, Multicentre Prospective Cohort Study (the SIREN Study); 2021. Available from: [http://dx.doi.
579 org/10.2139/ssrn.3790399](http://dx.doi.org/10.2139/ssrn.3790399).
- 580 [23] Lipsitch M, Kahn R. Interpreting vaccine efficacy trial results for infection and transmission. *medRxiv*.
581 2021;doi:10.1101/2021.02.25.21252415.

- 582 [24] Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with
583 SARS-CoV-2: a systematic review and meta-analysis. *The Lancet Global Health*. XXXX;doi:10.1016/S2214-
584 109X(21)00026-7.
- 585 [25] Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-
586 CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clinical Microbiology and Infection*.
587 2021;27(3):331–340. doi:10.1016/j.cmi.2020.10.020.
- 588 [26] Scientific Advisory Group for Emergencies. Imperial College London: Unlocking roadmap scenarios for
589 England, 18 February 2021; 2021. Available from: [https://www.gov.uk/government/publications/
590 imperial-college-london-unlocking-roadmap-scenarios-for-england-18-february-2021](https://www.gov.uk/government/publications/imperial-college-london-unlocking-roadmap-scenarios-for-england-18-february-2021).
- 591 [27] Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-pharmaceutical interventions
592 for COVID-19: a mathematical modelling study. *The Lancet Infectious Diseases*. XXXX;doi:10.1016/S1473-
593 3099(21)00143-2.
- 594 [28] Yang J, Marziano Veà. Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle?;
595 2021.
- 596 [29] Bauer S, Contreras S, Dehning J, Linden M, Iftekhar E, Mohr SB, et al.. Relaxing restrictions at the pace of
597 vaccination increases freedom and guards against further COVID-19 waves in Europe; 2021.
- 598 [30] Sabino EC, Buss LF, Carvalho MPS, Prete Jr CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19
599 in Manaus, Brazil, despite high seroprevalence. *The Lancet*. 2021;397(10273):452–455. doi:10.1016/S0140-
600 6736(21)00183-5.
- 601 [31] Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et al. Key ques-
602 tions for modelling COVID-19 exit strategies. *Proceedings of the Royal Society B: Biological Sciences*.
603 2020;287(1932):20201405. doi:10.1098/rspb.2020.1405.
- 604 [32] Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wiggert JHHM, Bonten MJM. Impact
605 of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *The Lancet Public
606 Health*. 2020;5(8):e452–e459. doi:10.1016/S2468-2667(20)30157-2.
- 607 [33] Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection fa-
608 cilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science*. 2020;368(6490):489–493.
609 doi:10.1126/science.abb3221.
- 610 [34] Chang SL, Harding N, Zachreson C, Cliff OM, Prokopenko M. Modelling transmission and control of the
611 COVID-19 pandemic in Australia. *Nature Communications*. 2020;11(1):5710. doi:10.1038/s41467-020-19393-6.

- 612 [35] Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MCJ, Rozhnova G. Impact of self-imposed pre-
613 vention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19
614 epidemic: A modelling study. *PLOS Medicine*. 2020;17(7):1–21. doi:10.1371/journal.pmed.1003166.
- 615 [36] Gatto M, Bertuzzo E, Mari L, Miccoli S, Carraro L, Casagrandi R, et al. Spread and dynamics of the COVID-
616 19 epidemic in Italy: Effects of emergency containment measures. *Proceedings of the National Academy of*
617 *Sciences*. 2020;117(19):10484–10491. doi:10.1073/pnas.2004978117.
- 618 [37] Pei S, Kandula S, Shaman J. Differential effects of intervention timing on COVID-19 spread in the United
619 States. *Science Advances*. 2020;6(49). doi:10.1126/sciadv.abd6370.
- 620 [38] Dehning J, Zierenberg J, Spitzner FP, Wibral M, Neto JP, Wilczek M, et al. Inferring change points in the spread
621 of COVID-19 reveals the effectiveness of interventions. *Science*. 2020;369(6500). doi:10.1126/science.abb9789.
- 622 [39] Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al. Modelling the COVID-
623 19 epidemic and implementation of population-wide interventions in Italy. *Nature Med*. 2020;26:855–860.
624 doi:10.1038/s41591-020-0883-7.
- 625 [40] Brett TS, Rohani P. Transmission dynamics reveal the impracticality of COVID-19 herd immunity strategies.
626 *Proceedings of the National Academy of Sciences*. 2020;117(41):25897–25903. doi:10.1073/pnas.2008087117.
- 627 [41] Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects in the transmission
628 and control of COVID-19 epidemics. *Nature Medicine*. 2020;26(8):1205–1211. doi:10.1038/s41591-020-0962-9.
- 629 [42] Bertuzzo E, Mari L, Pasetto D, Miccoli S, Casagrandi R, Gatto M, et al. The geography of COVID-19 spread
630 in Italy and implications for the relaxation of confinement measures. *Nature Communications*. 2020;11(1):4264.
631 doi:10.1038/s41467-020-18050-2.
- 632 [43] Rozhnova G, van Dorp CH, Bruijning-Verhagen P, Bootsma MCJ, van de Wijgert JHHM, Bonten MJM, et al.
633 Model-based evaluation of school- and non-school-related measures to control the COVID-19 pandemic. *Nature*
634 *Communications*. 2021;12(1):1614. doi:10.1038/s41467-021-21899-6.
- 635 [44] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine
636 prioritization strategies by age and serostatus. *Science*. 2021;371(6532):916–921. doi:10.1126/science.abe6959.
- 637 [45] Bartsch SM, O’Shea KJ, Ferguson MC, Bottazzi ME, Wedlock PT, Strych U, et al. Vaccine Efficacy Needed for
638 a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. *American Journal*
639 *of Preventive Medicine*. 2020;59(4):493–503. doi:10.1016/j.amepre.2020.06.011.
- 640 [46] Makhoul M, Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Al-Omari S, et al. Epidemio-
641 logical Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. *Vaccines*. 2020;8(4).
642 doi:10.3390/vaccines8040668.

- 643 [47] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first? *Science*
644 *Advances*. 2020;7(6). doi:10.1126/sciadv.abf1374.
- 645 [48] Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2
646 in the UK. medRxiv. 2020;doi:10.1101/2020.09.22.20194183.
- 647 [49] Borges V, Isidro J, Trovão N, Duarte S, Cortes-Martins H, Martiniano H, et al. The early dynamics of the
648 SARS-CoV-2 epidemic in Portugal. medRxiv. 2021;doi:10.1101/2021.02.22.21252216.
- 649 [50] Perra N. Non-pharmaceutical interventions during the COVID-19 pandemic: A review. Accepted for publication
650 in *Physics Reports*; 2021.
- 651 [51] Direção-Geral da Saúde. Ponto de Situação Atual em Portugal; 2021. Available from: [https://covid19.
652 min-saude.pt/](https://covid19.min-saude.pt/).
- 653 [52] Jing Q, Liu M, Zhang Z, Fang L, Yuan J, Zhang A, et al. Household secondary attack rate of COVID-19 and as-
654 sociated determinants in Guangzhou, China: a retrospective cohort study. *Lancet Infect Dis*. 2020;20(10):1141–
655 1150. doi:10.1016/S1473-3099(20)30471-0.
- 656 [53] Goldstein E, Lipsitch M, Cevik M. On the effect of age on the transmission of SARS-CoV-2 in households,
657 schools and the community. *The Journal of Infectious Diseases*. 2020;doi:10.1093/infdis/jiaa691.
- 658 [54] Kislaya I, Goncalves P, Barreto M, de Sousa R, Garcia AC, Matos R, et al. Seroprevalence of SARS-CoV-2
659 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). *Acta
660 Mdica Portuguesa*. 2021;34(2):87–94. doi:10.20344/amp.15122.
- 661 [55] Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors Associated with COVID-19
662 Vaccine Hesitancy. *Vaccines*. 2021;9(3). doi:10.3390/vaccines9030300.
- 663 [56] Veldhoen M, Simas JP. Endemic SARS-CoV-2 will maintain post-pandemic immunity. *Nature Reviews Im-
664 munology*. 2021;21(3):131–132. doi:10.1038/s41577-020-00493-9.
- 665 [57] Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-
666 CoV-2 through the postpandemic period. *Science*. 2020;368(6493):860–868. doi:10.1126/science.abb5793.
- 667 [58] Saad-Roy CM, Wagner CE, Baker RE, Morris SE, Farrar J, Graham AL, et al. Immune life history,
668 vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. *Science*. 2020;370(6518):811–818.
669 doi:10.1126/science.abd7343.
- 670 [59] Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to
671 endemicity. *Science*. 2021;371(6530):741–745. doi:10.1126/science.abe6522.

- 672 [60] Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of
673 anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.
674 *European Journal of Immunology*. 2020;50(12):2025–2040. doi:<https://doi.org/10.1002/eji.202048970>.
- 675 [61] Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human
676 antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Science*
677 *Immunology*. 2020;5(52). doi:10.1126/sciimmunol.abe0367.
- 678 [62] Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies
679 to SARS-CoV-2 infection persist for months. *Science*. 2020;370(6521):1227–1230. doi:10.1126/science.abd7728.
- 680 [63] Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan Wh, Chiu SS, et al. Neutralizing antibody titres in
681 SARS-CoV-2 infections. *Nature Communications*. 2021;12(1):63. doi:10.1038/s41467-020-20247-4.
- 682 [64] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2
683 assessed for up to 8 months after infection. *Science*. 2021;371(6529). doi:10.1126/science.abf4063.
- 684 [65] Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2
685 variant B.1.351 from natural and vaccine-induced sera. *Cell*. XXXX;doi:10.1016/j.cell.2021.02.037.
- 686 [66] Contemporary Portugal Database (Pordata); 2020. Available from: <https://www.pordata.pt/>.
- 687 [67] Mistry D, Litvinova M, Pastore y Piontti A, Chinazzi M, Fumanelli L, Gomes MFC, et al. Inferring
688 high-resolution human mixing patterns for disease modeling. *Nature Communications*. 2021;12(1):323.
689 doi:10.1038/s41467-020-20544-y.
- 690 [68] Backer JA, Mollema L, Vos ER, Klinkenberg D, van der Klis FR, de Melker HE, et al. Impact of physical distanc-
691 ing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Nether-
692 lands, 2016/17, April 2020 and June 2020. *Eurosurveillance*. 2021;26(8). doi:[https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2021.26.8.2000994)
693 [7917.ES.2021.26.8.2000994](https://doi.org/10.2807/1560-7917.ES.2021.26.8.2000994).
- 694 [69] Rozhnova G, Kretzschmar ME, van der Klis F, van Baarle D, Korndewal M, Vossen AC, et al. Short-
695 and long-term impact of vaccination against cytomegalovirus: a modeling study. *BMC Med*. 2020;18.
696 doi:<https://doi.org/10.1186/s12916-020-01629-3>.
- 697 [70] Carpenter B, Gelman A, Hoffman M, Lee D, Goodrich B, Betancourt M, et al. Stan: A probabilistic program-
698 ming language. *J Stat Softw*. 2017;76(1):1–32. doi:10.18637/jss.v076.i01.
- 699 [71] Diekmann O, Heesterbeek JAP, Roberts MG. The construction of next-generation matrices for compartmental
700 epidemic models. *Journal of The Royal Society Interface*. 2010;7(47):873–885. doi:10.1098/rsif.2009.0386.

701 **Acknowledgements**

702 G.R., J.V., A.N., M.C.G. were supported by FCT project reference 131_596787873, awarded to G.R. M.V. was
703 supported by the European Union H2020 ERA project (No 667824 EXCELLtoINNOV). The contribution of
704 C.H.v.D. was under the auspices of the US Department of Energy (contract number 89233218CNA000001) and
705 supported by the National Institutes of Health (grant number R01-OD011095).

706 **Author contributions**

707 G.R. conceived and supervised the study. G.R. and J.V. developed the transmission model. C.H.v.D. developed
708 the observation model. J.V. conducted preliminary model analyses. G.R. conducted all final analyses, prepared
709 figures and wrote the manuscript. A.N., M.C.G., M.v.B., M.E.K, and M.V. provided data, validated the model and
710 analyses. All authors contributed to interpretation of the results, writing the final version of the manuscript and
711 gave final approval for publication.

712 **Competing interests**

713 The authors declare no competing interests.

714 **Additional information**

715 Supplementary Figures and Tables are given at the end of the manuscript.

716 **Correspondence**

717 Correspondence and material requests should be addressed to Dr. Ganna Rozhnova, Julius Center for Health
718 Sciences and Primary Care, University Medical Center Utrecht, P.O. Box 85500 Utrecht, The Netherlands; email:
719 g.rozhnova@umcutrecht.nl.

Supplementary Figures and Tables




Figure S1. Estimated hospitalization rates. The histograms of age-specific hospitalization rates estimated by the model. The solid and the dashed lines are, respectively, the medians and the 95% credible intervals based on 2,000 parameter samples from the posterior distribution.




Figure S2. Estimated model parameters. The histograms of model parameter estimates. The solid and the dashed lines are, respectively, the medians and the 95% credible intervals based on 2,000 parameter samples from the posterior distribution. Time $t = 0$ corresponds to 26 February 2020.




Figure S3. Age-specific vaccination rates. Vaccination rate (number of persons vaccinated per day) per age group calculated using the national vaccination plan (Table 1) and age distribution of various vaccination categories (Figure 4 a). The vertical lines indicate the starting dates of different phases of vaccination (Table 1). According to the current guidelines persons under 18 years old are not eligible for vaccination. In the model, we assumed that the age group of 0 to 20 years old is not vaccinated.




Figure S4. Number of vaccinated persons per age group during the vaccination rollout. These numbers were calculated using the national vaccination plan (Table 1) and age distribution of various vaccination categories (Figure 4 a). The vertical lines indicate the starting dates for vaccination of different phases of vaccination (Table 1). According to the current guidelines persons under 18 years old are not eligible for vaccination. In the model, we assumed that the age group of 0 to 20 years old is not vaccinated.




Figure S5. Infectious cases dynamics. New daily cases of SARS-CoV-2 for Scenario 4 presented in Figure 7 in the main text. The black line is the median trajectory estimated from the model. The gray shaded region corresponds to 95% credible intervals. The blue vertical lines indicate the mid-points of relaxation steps (1 April, 1 June, 1 October). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1).




Figure S6. Impact of timings of different relaxation steps. Total daily hospital admissions with COVID-19 and proportion of protected population for Scenario 4 (Figure 7 in the main text) with Step 3 occurring on 1 August instead of 1 October 2021. The hospitalization data are shown as red dots. The solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals. The blue vertical lines indicate the mid-points of relaxation steps (1 April, 1 June, 1 August). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1).

Table S1. ICPC-2 codes for morbidities specified in the Portuguese vaccination plan.

Morbidities	ICPC-2 code
Cardiac insufficiency	K75, K77
Coronary heart disease	K74, K76
Renal insufficiency	U99 and GFR < 60 ml/min
COPD	R95 or another chronic respiratory disease requiring ventilation
Diabetes	T89, T90
Neoplasm	A79, B72-74, D74-76, F74, H75, K72, L71, N74, R84-85, S77, T71, T73, U75-77, X75-77, Y77-78
Hepatic insufficiency	D97
Obesity	T82
High blood pressure	K86, K87




Figure S7. Impact of vaccine efficacies and contact rates of vaccinated individuals. Scenario 4 (Figure 7 in the main text) but with a pessimistic set of vaccine efficacies (Table S2). In addition to using a pessimistic set of vaccine efficacies, we allow for behavior compensation post-vaccination modelled as a return to pre-pandemic contact rates among vaccinated persons as compared to unvaccinated persons who may continue to have reduced contact rates due to control measures. The hospitalization data are shown as red dots. The solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals. The blue vertical lines indicate the mid-points of relaxation steps (1 April, 1 June, 1 October 2021). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1).

Table S2. Summary of the model parameters.

Description (unit)	Notation	Reference
Constant parameters		
Latent period (days)	$1/\alpha$	Estimated
Infectious period (days)	$1/\gamma$	Estimated
Over-dispersion parameter for the NegBinom distribution for hospitalizations	ϕ	Estimated
Initial fraction of infected persons	θ	Estimated
Probability of transmission per contact	ϵ	Estimated
Age-specific parameters*		
Force of infection for unvaccinated and vaccinated persons (1/day)	$\lambda_k(t), \lambda_k^V(t)$	Eqs. (3) and (4)
Contact rate for unvaccinated persons (1/day)	$c_{kl}(t)$	Estimated, see Table S4
Contact rate for vaccinated persons (1/day)	$c_{kl}^V(t)$	Assumed
Hospitalization rate (1/day)	ν_k	Estimated
Susceptibility of age group k relative to age group $n = 10$	β_k	Estimated
Population size of age group k	N_k	[66]
Vaccination parameters*		
Vaccination rate (1/day)	r_k	Calculated from Table 1 and Figure 4 a
Vaccine efficacy in reducing susceptibility	VE_S	94% (optimistic), 55% (pessimistic) [15, 18–23, 26]
Vaccine efficacy in reducing infectivity	VE_I	0% (optimistic), 0% (pessimistic) [15, 18–23, 26]
Vaccine efficacy in reducing hospitalization rate	VE_H	67% (optimistic), 0% (pessimistic) [15, 18–23, 26]

*Indices k and l denote the age groups $k, l = 1, \dots, n$, where $n = 10$ is the number of age groups.

Table S3. Prior distribution of the statistical model.

Parameter	Prior	Description
ϵ	Uniform(0, 1)	Flat prior
θ	Uniform(10^{-7} , $5 \cdot 10^{-4}$)	Vague prior allowing for 1 to 5000 infected individuals on day $t = 0$
ϕ	Lognormal(5, 2)	Vague prior ^a
α	InvGamma(32.25, 9.75)	99% of the prior density of α^{-1} is between 2 and 5 days
γ	InvGamma(80, 20)	95% of the prior density of γ^{-1} is between 5.3 and 8.2 days
ν_k	folded- $\mathcal{N}(0, 5)$	Vague prior, where k denotes [0, 5), [5, 10), [10, 20), [20, 30), [30, 40), [40, 50), [50, 60), [60, 70), [70, 80), 80+
$\beta_{(0,20)}$	LogNormal(log(0.23), 0.5)	Odds-ratio ^b 2.23 based on prior estimates [52]
$\beta_{[20,60)}$	LogNormal(log(0.64), 0.5)	Odds-ratio ^b 0.64 based on prior estimates [52]
ζ	$\mathcal{N}(1, 0.1)$	<i>A priori</i> , ζ should be close to 1
u_i	Uniform(0, 1)	Flat prior ($i = 1, \dots, 4$)
K_i	Exp(1)	With $K_i = 1$, the uptake of control measures takes approximately 6 days ($i = 0, \dots, 4$)
t_0	$\mathcal{N}(22, 7)$	First lockdown around 18 March 2020 (State of Emergency)
$t_1 - 2.94/K_1$	$\mathcal{N}(69, 7)$	Start of relaxation of lockdown around 4 May 2020 2020 ^c
t_2	$\mathcal{N}(203, 7)$	Further relaxation on 15 September 2020 (school opening)
t_3	$\mathcal{N}(254, 7)$	Second lockdown 05 November 2020 (State of Emergency)
t_4	$\mathcal{N}(304, 7)$	Relaxation of second lockdown on 25 December 2020

Notes: ^aThe scale parameters of the normal distributions are equal to the standard deviation. ^bThe age class 60+ is taken as a reference for the relative susceptibility, i.e., $\beta_{60+} \equiv 1$. ^cThe prior on the time of relaxation of the first lockdown is put on the time where the logistic function equals 5%. Notice that $\text{logit}(0.05) = -2.94$.

Table S4. Parameters describing contact structure.

Description (unit)	Notation*	Reference
Contact rates (1/day)		
Baseline (pre-pandemic)	b_{kl}	[67]
After the first lockdown	ζa_{kl}	ζ estimated, a_{kl} inferred using [68]
After the first relaxation	$u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$	Estimated
After the second relaxation due to school opening	$u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$	Estimated
After the second lockdown	$u_3 b_{kl} + (1 - u_3) \zeta a_{kl}$	Estimated
After the relaxation due to winter holidays	$u_4 b_{kl} + (1 - u_4) \zeta a_{kl}$	Estimated
After the third lockdown	ζa_{kl}	Assumed
After first relaxation during the vaccination rollout (Scenario 1)	b_{kl}	Assumed
After first relaxation during the vaccination rollout (Scenario 2)	$u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$	Assumed
After first relaxation during the vaccination rollout (Scenario 3)	$u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$	Assumed
After first, second, third relaxation during the vaccination rollout (Scenario 4)	Matrices for Scenario 3, 2, 1	Assumed
Mid-point time of the logistic function (days)		
Introduction of the first lockdown	t_0	Estimated
Relaxation after the first lockdown	t_1	Estimated
Second relaxation due to school opening	t_2	Estimated
Introduction of the second lockdown	t_3	Estimated
Relaxation due to winter holidays	t_4	Estimated
Introduction of the third lockdown	t_5	28 January 2021, Assumed
First relaxation during the vaccination rollout	t_6	1 April 2021, Assumed
Second relaxation during the vaccination rollout	t_7	1 June 2021, Assumed
Third relaxation during the vaccination rollout	t_8	1 October 2021 (main analyses), 1 August (sensitivity analyses), Assumed
Slope of the logistic function (1/day)		
Introduction of the first lockdown	K_0	Estimated
Relaxation after the first lockdown	K_1	Estimated
Second relaxation due to school opening	K_2	Estimated
Introduction of the second lockdown	K_3	Estimated
Relaxation due to winter holidays	K_4	Estimated
Introduction of the third lockdown	K_0	Assumed
First relaxation during the vaccination rollout	K_1	Assumed
Second relaxation during the vaccination rollout	K_1	Assumed
Third relaxation during the vaccination rollout	K_1	Assumed
Proportion of time a person behaves as before the pandemic		
Relaxation after the first lockdown	u_1	Estimated
Second relaxation due to school opening	u_2	Estimated
Introduction of the second lockdown	u_3	Estimated
Relaxation due to winter holidays	u_4	Estimated

*Indices k and l denote the age groups $k, l = 1, \dots, n$, where $n = 10$ is the number of age groups.